Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Tumor Necrosis Factor Displays Anti-Inflammatory Behavior in Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 09 Jun 2011
Print article
The proinflammatory protein tumor necrosis factor (TNF) has been found to have an additional, previously unsuspected anti-inflammatory function that might be coopted for treatment of chronic inflammatory conditions such as rheumatoid arthritis.

Investigators at the Hospital for Special Surgery (New York, NY, USA) worked with an in vitro model in which human monocytes and macrophages - cells that have a key role in inflammatory diseases - were treated with TNF and then challenged with LPS (lipopolysaccharide), a potent inflammatory factor that stimulates receptors important in inflammation.

They reported in the May 22, 2011, online edition of the journal Nature Immunology that TNF suppressed the inflammatory response of the macrophages and monocytes. Furthermore, in a set of in vivo experiments they found that mice treated with low doses of TNF were protected from subsequent lethal high doses of LPS. Suppression of the inflammatory response by TNF involved the protein GSK3 (glycogen synthase kinase 3-alpha) as well as the TNFAIP3 gene, which encodes the A20 protein.

"We think it is relevant to rheumatoid arthritis, not only because the cells we are studying (the macrophages) are exactly the same cells that migrate into joints and make the inflammatory cytokines involved in rheumatoid arthritis, but because A20 is involved," said senior author Dr. Lionel Ivashkiv, associate chief scientific officer at the Hospital for Special Surgery. "TNFAIP3 is one of the best linked genes to rheumatoid arthritis. There are polymorphisms in the A20 gene that have been linked to rheumatoid arthritis pathogenesis."

"Prior to this study, TNF has long been known as a potent proinflammatory cytokine, but if you look carefully through the literature, there are hints that it also has some suppressive functions, but nothing was known about the mechanisms," said Dr. Ivashkiv. "This is really the first mechanism showing how TNF can turn inflammation down."

Related Links:
Hospital for Special Surgery


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.